Regulatory B cells in myasthenia gravis are differentially affected by therapies

We analyzed the number and functionality of regulatory B (Breg) cells in well‐defined myasthenia gravis patients. We first showed a decreased number of circulating CD19(+) CD24(++) CD38(++) Breg cells and an altered functionality of Breg cells in untreated myasthenia gravis patients. Next, we demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Yilmaz, Vuslat, Maillard, Solène, Truffault, Frédérique, Bolgert, Francis, Behin, Anthony, Regnard, Jean‐François, Berrih‐Aknin, Sonia, Le Panse, Rozen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243377/
https://www.ncbi.nlm.nih.gov/pubmed/30480034
http://dx.doi.org/10.1002/acn3.645
_version_ 1783371970899869696
author Yilmaz, Vuslat
Maillard, Solène
Truffault, Frédérique
Bolgert, Francis
Behin, Anthony
Regnard, Jean‐François
Berrih‐Aknin, Sonia
Le Panse, Rozen
author_facet Yilmaz, Vuslat
Maillard, Solène
Truffault, Frédérique
Bolgert, Francis
Behin, Anthony
Regnard, Jean‐François
Berrih‐Aknin, Sonia
Le Panse, Rozen
author_sort Yilmaz, Vuslat
collection PubMed
description We analyzed the number and functionality of regulatory B (Breg) cells in well‐defined myasthenia gravis patients. We first showed a decreased number of circulating CD19(+) CD24(++) CD38(++) Breg cells and an altered functionality of Breg cells in untreated myasthenia gravis patients. Next, we demonstrated that the proportion of circulating Breg cells was restored in myasthenia gravis patients after thymectomy, probably as Breg cells could be sequestered in the myasthenia gravis thymus. In contrast, corticosteroid treatments did not restore and decreased even more the proportion of Breg cells in myasthenia gravis patients. These results clearly demonstrated that two distinct immunomodulatory therapies affect differentially Breg cells.
format Online
Article
Text
id pubmed-6243377
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62433772018-11-26 Regulatory B cells in myasthenia gravis are differentially affected by therapies Yilmaz, Vuslat Maillard, Solène Truffault, Frédérique Bolgert, Francis Behin, Anthony Regnard, Jean‐François Berrih‐Aknin, Sonia Le Panse, Rozen Ann Clin Transl Neurol Brief Communication We analyzed the number and functionality of regulatory B (Breg) cells in well‐defined myasthenia gravis patients. We first showed a decreased number of circulating CD19(+) CD24(++) CD38(++) Breg cells and an altered functionality of Breg cells in untreated myasthenia gravis patients. Next, we demonstrated that the proportion of circulating Breg cells was restored in myasthenia gravis patients after thymectomy, probably as Breg cells could be sequestered in the myasthenia gravis thymus. In contrast, corticosteroid treatments did not restore and decreased even more the proportion of Breg cells in myasthenia gravis patients. These results clearly demonstrated that two distinct immunomodulatory therapies affect differentially Breg cells. John Wiley and Sons Inc. 2018-09-22 /pmc/articles/PMC6243377/ /pubmed/30480034 http://dx.doi.org/10.1002/acn3.645 Text en © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communication
Yilmaz, Vuslat
Maillard, Solène
Truffault, Frédérique
Bolgert, Francis
Behin, Anthony
Regnard, Jean‐François
Berrih‐Aknin, Sonia
Le Panse, Rozen
Regulatory B cells in myasthenia gravis are differentially affected by therapies
title Regulatory B cells in myasthenia gravis are differentially affected by therapies
title_full Regulatory B cells in myasthenia gravis are differentially affected by therapies
title_fullStr Regulatory B cells in myasthenia gravis are differentially affected by therapies
title_full_unstemmed Regulatory B cells in myasthenia gravis are differentially affected by therapies
title_short Regulatory B cells in myasthenia gravis are differentially affected by therapies
title_sort regulatory b cells in myasthenia gravis are differentially affected by therapies
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243377/
https://www.ncbi.nlm.nih.gov/pubmed/30480034
http://dx.doi.org/10.1002/acn3.645
work_keys_str_mv AT yilmazvuslat regulatorybcellsinmyastheniagravisaredifferentiallyaffectedbytherapies
AT maillardsolene regulatorybcellsinmyastheniagravisaredifferentiallyaffectedbytherapies
AT truffaultfrederique regulatorybcellsinmyastheniagravisaredifferentiallyaffectedbytherapies
AT bolgertfrancis regulatorybcellsinmyastheniagravisaredifferentiallyaffectedbytherapies
AT behinanthony regulatorybcellsinmyastheniagravisaredifferentiallyaffectedbytherapies
AT regnardjeanfrancois regulatorybcellsinmyastheniagravisaredifferentiallyaffectedbytherapies
AT berrihakninsonia regulatorybcellsinmyastheniagravisaredifferentiallyaffectedbytherapies
AT lepanserozen regulatorybcellsinmyastheniagravisaredifferentiallyaffectedbytherapies

Ejemplares similares